ECM
NPCE icon

ExodusPoint Capital Management’s Neuropace NPCE Stock Holding History

ExodusPoint Capital Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,803
Closed -$491K – 1924
2025
Q4 		$491K Buy
+31,803
New +$425K ﹤0.01% 1187
2024
Q2 		– Sell
-19,431
Closed -$256K – 1833
2024
Q1 		$256K Sell
19,431
-360
-2% -$5.13K ﹤0.01% 1298
2023
Q4 		$204K Buy
+19,791
New +$158K ﹤0.01% 1273

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ExodusPoint Capital Management's NPCE Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Neuropace (NPCE) in Q1 2026, closing a stake of 31,803 shares — an estimated $491K sold.

ExodusPoint Capital Management first reported a position in NPCE in Q4 2023 and held it in 3 quarters. The position peaked at $491K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • ExodusPoint Capital Management reported no remaining Neuropace position as of Q1 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 31,803 Neuropace shares in Q1 2026, an estimated $491K.
  • ExodusPoint Capital Management first reported a position in Neuropace in Q4 2023 and held it in 3 quarters.
  • ExodusPoint Capital Management's Neuropace position peaked at $491K in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.